UCB and Amgen have collaborated on the development of a novel Osteoperosis treatment for nearly twenty years. Alliance management has been central to navigating the collaboration through the impact of numerous internal and external factors. Following a succesful global launch, it is now time to reflect and share the learnings from collaboration and prepare for continued future success following the development to commercialization alliance inflection point.
Exemplified through the use of case stuidies, insights will be given as to how alliance management interviened at critical inflection points, including to manage times of mis-salignement and to optimise the operating model.
Tracy Blois, Phd
Director, Alliance Management Business Development
Tracy has spent more than a decade working in biotechnology and presently works as a director in Alliance Management with Amgen's Business Development group. In this role, she has managed a diverse set of early and late stage partnerships across Amgen's portfolio. Previously, as the head of Business Development's Operations group, she led a team to support the successful identification, evaluation, and execution of licensing and equity collaborations across the company. Tracy brings additional past experience in quality control, technology transfer, and biochemistry research.Tracy is an active member of the STEM outreach community, serving as a mentor with Amgen's mentoring program and as a past president of the local Association for Women in Science (AWIS) chapter.Tracy earned a Ph.D. in Biochemistry and Molecular Biology from UCLA and a BA in Biochemistry from the University of San Diego.
Alistair Dixon, PhD
Senior Director Alliance Management
Alistair has worked in the pharmaceutical industry for over 20 years, during which time he has gained a broad range of experience from early stage discovery through to late stage development, approval and launch. Alistair has worked as a dedicated alliance manager for 10 years, at GSK, Takeda and now at UCB. During this time, he has managed alliances and complex collaborations on assets that span from candidate selection through to late stage development, filing and launch. Alistair holds a PhD in Pharmacology from the University of Cambridge.